Candriam S.C.A. Day One Biopharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 290,014 shares of DAWN stock, worth $3.66 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
290,014
Previous 290,014
-0.0%
Holding current value
$3.66 Million
Previous $4 Million
1.08%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
84MCall Options Held
144KPut Options Held
218K-
Ra Capital Management, L.P. Boston, MA7.87MShares$99.3 Million1.53% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$81.1 Million11.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.89MShares$74.3 Million0.0% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$61.5 Million1.92% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$57.2 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $927M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...